Trial Profile
Efficacy and Safety of Apatinib Combined With Dose-dense Temozolomide in Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide (Primary)
- Indications CNS cancer; Glioblastoma
- Focus Therapeutic Use
- 17 Sep 2018 New trial record